NEW YORK & LAVAL, Quebec--(BUSINESS WIRE)--Auven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs and Bellus Health Inc. (TSX: BLU), a drug development company focused on rare diseases, today announced that Auven has entered into a license agreement with the Icahn School of Medicine at Mount Sinai in New York, under which Auven obtains rights to develop KIACTA™ (eprodisate) as a treatment for chronic sarcoidosis.
Help employers find you! Check out all the jobs and post your resume.
